Eisai And Takeda Strengthen Production System To Prepare For Possible Flu Pandemic
This article was originally published in PharmAsia News
According to Japan Pharmaceutical Manufacturers Association's guidelines on flu pandemic preparation measures, which were upated last July, drug makers are responsible to continue providing drugs to patients. JPMA's guideline further calls 70 member companies to prepare drug supplies amid a flu pandemic that could last more than two months. Eisai has since increased dementia and cancer drug production in its seven factories worldwide, and assured a two month supply even if one of the factories stopped operation. Starting this year, Takeda plans to establish a system that will be able to produce two months of supply of all products in case Takeda's seven factories worldwide stop production for two months. (Click here for more - Japanese language)
You may also be interested in...
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. The first of a two-part series on mental health focuses on transcranial magnetic stimulation systems. See what Neuronetics’ CEO Stephen Furlong said about it here.
US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.
Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.